Puma Biotechnology (PBYI) Other Non-Current Assets (2011 - 2026)
Puma Biotechnology (PBYI) posted Other Non-Current Assets of $2.7 million for Q1 2026, down 0.6% on a QoQ basis from $2.7 million in Q4 2025, and up 26.52% year-over-year from $2.1 million in Q1 2025.
Puma Biotechnology (PBYI) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Puma Biotechnology's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- Quarterly Other Non-Current Assets rose 26.52% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 26.52% YoY) and the FY2025 annual result came in at $2.7 million, up 27.29% from the prior year.
- Other Non-Current Assets was $2.7 million for Q1 2026 at Puma Biotechnology, down from $2.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.3 million in Q1 2022 and bottomed at $217000.0 in Q3 2022.
- A 5-year average of $2.1 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 93.45% — and 2023, when it soared 1162.67%.
- Puma Biotechnology's Other Non-Current Assets stood at $2.1 million in 2022, then increased by 1.5% to $2.1 million in 2023, then changed by 0.0% to $2.1 million in 2024, then gained by 27.29% to $2.7 million in 2025, then slipped by 0.6% to $2.7 million in 2026.
- Business Quant data shows PBYI's Other Non-Current Assets at $2.7 million in Q1 2026, $2.7 million in Q4 2025, and $2.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.66 Mn |
| Dec 31, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 2.74 Mn |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 2.07 Mn |
| Sep 30, 2022 | 217,000.00 |
| Jun 30, 2022 | 504,000.00 |
| Mar 31, 2022 | 3.30 Mn |
| Dec 31, 2021 | 1.35 Mn |
| Sep 30, 2021 | 3.31 Mn |
| Jun 30, 2021 | 1.46 Mn |
| Mar 31, 2021 | 3.31 Mn |